4/9/2023 0 Comments Cleanspark public offering![]() In response, Penumbra’s stock price fell 7%, from $188.82 per share on Decemto $174.98 per share on December 16, 2020, a decline of $13.84 per share. Most recently, on December 15, 2020, the Company issued a press release announcing that it was issuing an “urgent” and “voluntary” recall of the Jet 7 Xtra Flex because the catheter “may become susceptible to distal tip damage during use” which could lead to injury or death. The truth emerged through a series of disclosures that caused Penumbra’s stock price to fall and investors to suffer substantial losses. market in July 2019 and quickly became a “growth driver” for the Company, a key source of new revenues. The Jet 7 Xtra Flex was introduced to the U.S. Until recently, one of the Company’s flagship products was the “Jet 7 Xtra Flex,” an aspiration catheter designed to be inserted into an affected artery, navigated to a blood clot, and used to suck the clot out of the patient’s body. Penumbra is a global healthcare company that develops, manufactures and sells innovative medical devices for patients suffering from stroke and other vascular and neurovascular diseases. Additional information about each case can be found at the link provided. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. 10, 2021 (GLOBE NEWSWIRE) - Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Penumbra, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |